BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 11126989)

  • 1. [Undesirable drug interactions of hypolipemic drugs].
    Chojnowska-Jezierska J
    Pol Merkur Lekarski; 2000 Sep; 9(51):618-20. PubMed ID: 11126989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Metabolic interactions with statins].
    Molden E; Asberg A
    Tidsskr Nor Laegeforen; 2001 Jan; 121(2):189-93. PubMed ID: 11475198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statin safety and drug interactions: clinical implications.
    Bottorff MB
    Am J Cardiol; 2006 Apr; 97(8A):27C-31C. PubMed ID: 16581325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions.
    Shitara Y; Sugiyama Y
    Pharmacol Ther; 2006 Oct; 112(1):71-105. PubMed ID: 16714062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.
    Williams D; Feely J
    Clin Pharmacokinet; 2002; 41(5):343-70. PubMed ID: 12036392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.
    Jacobson TA
    Am J Cardiol; 2004 Nov; 94(9):1140-6. PubMed ID: 15518608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update.
    Schachter M
    Fundam Clin Pharmacol; 2005 Feb; 19(1):117-25. PubMed ID: 15660968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rhabdomyolysis in association with simvastatin and amiodarone.
    Roten L; Schoenenberger RA; Krähenbühl S; Schlienger RG
    Ann Pharmacother; 2004 Jun; 38(6):978-81. PubMed ID: 15069169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the synergistic adverse effects of concomitant therapy with statins and fibrates on rhabdomyolysis.
    Matzno S; Tazuya-Murayama K; Tanaka H; Yasuda S; Mishima M; Uchida T; Nakabayashi T; Matsuyama K
    J Pharm Pharmacol; 2003 Jun; 55(6):795-802. PubMed ID: 12841940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of P-glycoprotein in statin drug interactions.
    Holtzman CW; Wiggins BS; Spinler SA
    Pharmacotherapy; 2006 Nov; 26(11):1601-7. PubMed ID: 17064205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.
    Schmidt GA; Hoehns JD; Purcell JL; Friedman RL; Elhawi Y
    J Am Board Fam Med; 2007; 20(4):411-6. PubMed ID: 17615423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antilipemic therapy and rhabdomyolysis].
    Paragh G; Balogh Z; Romics L
    Orv Hetil; 2003 Mar; 144(11):515-20. PubMed ID: 12731338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8.
    Tornio A; Pasanen MK; Laitila J; Neuvonen PJ; Backman JT
    Basic Clin Pharmacol Toxicol; 2005 Aug; 97(2):104-8. PubMed ID: 15998357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan.
    Saito M; Hirata-Koizumi M; Urano T; Miyake S; Hasegawa R
    J Clin Pharm Ther; 2005 Feb; 30(1):21-37. PubMed ID: 15659001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Myopathy with rhabdomyolysis as an adverse effect of simultaneous treatment with cerivastatin and gemfibrozil].
    Huić M; Anić B; Cikes N; Bosnić D; Sentić M; Markeljević J; Mayer M; Pazanin L
    Lijec Vjesn; 2002; 124(3-4):73-6. PubMed ID: 18956824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics of statins.
    García MJ; Reinoso RF; Sánchez Navarro A; Prous JR
    Methods Find Exp Clin Pharmacol; 2003; 25(6):457-81. PubMed ID: 12949632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential drug interaction between simvastatin and danazol causing rhabdomyolysis.
    Andreou ER; Ledger S
    Can J Clin Pharmacol; 2003; 10(4):172-4. PubMed ID: 14712320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A further point about statins...
    Gilden D
    GMHC Treat Issues; 1998 Jun; 12(6):8. PubMed ID: 11365725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States].
    Saito M; Hirata-Koizumi M; Miyake S; Hasegawa R
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2005; (123):41-5. PubMed ID: 16541751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.